| Ambulance Policy, Professional | Commercial | 21 | Original policy ↗ |
| Ambulance Services | MP.001.25 · Effective Jun 1, 2026 · Commercial | 30 | Original policy ↗ |
| Ambulatory EEG Monitoring | MMP379.12 · Effective Sep 1, 2026 | 26 | Original policy ↗ |
| Ambulatory Electrocardiographic (AECG) Monitoring | MMP109.19 · Effective Sep 1, 2026 | 25 | Original policy ↗ |
| Amondys 45® (Casimersen) | 2026D0105I · Effective May 1, 2026 · Commercial | 1 | Original policy ↗ |
| Anatomical Modifier Requirement Policy, Professional | 2026R5033C · Commercial | 23 | Original policy ↗ |
| Anesthesia Policy, Professional | 2026R0032A · Commercial | 222 | Original policy ↗ |
| Apheresis – Commercial and Individual Exchange Medical Policy | 2026T0136KK · Commercial | 7 | Original policy ↗ |
| Assistant-at-Surgery Services Policy, Professional | Commercial | 10 | Original policy ↗ |
| Autoimmune Rheumatic Disease Policy, Professional and Facility | 2026R8007A · Effective Dec 1, 2025 · Commercial | 7 | Original policy ↗ |
| Autologous Cellular Therapy | 2026T0612N · Effective Oct 1, 2026 · Commercial | 13 | Original policy ↗ |
| Bariatric Surgery | 2026T0362RR · Effective May 1, 2026 · Commercial | 31 | Original policy ↗ |
| Beds and Mattresses | MP.028.15 · Effective Jul 1, 2026 · Commercial | 33 | Original policy ↗ |
| Benlysta® (Belimumab) | 2025E0046S · Effective Dec 1, 2025 · Commercial | 1 | Original policy ↗ |
| Bilateral Procedures Policy, Professional | Commercial | 10 | Original policy ↗ |
| Bone Turnover Marker Testing of Osteoporosis Policy, Professional and Facility | 2026R8004A · Effective Aug 26, 2026 · Commercial | 4 | Original policy ↗ |
| Botulinum Toxins A and B | 2026D0017AN · Effective Jan 1, 2026 · Commercial | 5 | Original policy ↗ |
| Breast Imaging for Screening and Diagnosing Cancer | 2026T0375LL · Effective Feb 1, 2026 · Commercial | 16 | Original policy ↗ |
| Breast Reconstruction | MP.003.29 · Effective Jan 1, 2026 · Commercial | 33 | Original policy ↗ |
| Breast Reduction Surgery | MP.004.32 · Effective Jun 1, 2026 · Commercial | 1 | Original policy ↗ |
| Brineura® (Cerliponase Alfa) | 2025D0065M · Effective Nov 1, 2025 · Commercial | 1 | Original policy ↗ |
| Briumvi® (Ublituximab-Xiiy) | 2026D0122F · Effective Jan 1, 2026 · Commercial | 1 | Original policy ↗ |
| Bronchial Thermoplasty | 2026T0542AA · Effective Oct 1, 2026 · Commercial | 2 | Original policy ↗ |
| Brow Ptosis and Eyelid Repair | MP.002.29 · Effective Aug 1, 2026 · Commercial | 27 | Original policy ↗ |
| Brow Ptosis and Eyelid Repair | MMP007.10 · Effective Sep 1, 2026 | 16 | Original policy ↗ |
| Buprenorphine (Brixadi® & Sublocade®) | 2026D0057T · Effective Oct 1, 2026 · Commercial | 4 | Original policy ↗ |
| Capsule Endoscopy | MMP036.15 · Effective Sep 1, 2026 | 5 | Original policy ↗ |
| Cardiovascular Diagnostic and Therapeutic Procedures | MMP013.22 · Effective Sep 1, 2026 | 30 | Original policy ↗ |
| Cardiovascular Disease Risk Tests | 2026T0389FF · Effective Oct 1, 2026 · Commercial | 16 | Original policy ↗ |
| Care Plan Oversight Policy, Professional | Effective Jun 1, 2026 · Commercial | 21 | Original policy ↗ |
| Carrier Testing Panels for Genetic Diseases | 2026T0586T · Effective Jul 1, 2026 · Commercial | 4 | Original policy ↗ |
| Category III Codes | 2026T0644R · Effective Oct 1, 2026 · Commercial | 184 | Original policy ↗ |
| Category III CPT Codes | MMP043.50 · Effective Oct 1, 2026 | 116 | Original policy ↗ |
| Catheter Ablation for Atrial Fibrillation | 2026T0609R · Effective Jun 1, 2026 · Commercial | 4 | Original policy ↗ |
| Cell-Free Fetal DNA Testing | 2026T0560NN · Effective Oct 1, 2026 · Commercial | 10 | Original policy ↗ |
| Chelation Therapy | 2026T0051EE · Effective Jul 1, 2026 · Commercial | 8 | Original policy ↗ |
| Chemotherapy Observation or Inpatient Hospitalization – Commercial and Individual Exchange Medical Policy | MP.02.21 · Commercial | — | Original policy ↗ |
| Chromosome Microarray Testing (Non-Oncology Conditions) | 2026T0559GG · Effective Jun 1, 2026 · Commercial | 7 | Original policy ↗ |
| Chronic Heart Failure Policy, Professional and Facility | 2026R8008A · Effective Aug 26, 2026 · Commercial | 1 | Original policy ↗ |
| Cimzia® (Certolizumab Pegol) | 2026D0083L · Effective Feb 1, 2026 · Commercial | 1 | Original policy ↗ |
| Clinical Diagnostic Laboratory Services | MMP185.46 · Effective Aug 1, 2026 | 9 | Original policy ↗ |
| Clinical Laboratory Improvement Amendments (CLIA) ID Requirement Policy, Professional | Commercial | — | Original policy ↗ |
| Clinical Trials | MP.006.27 · Effective Sep 1, 2026 · Commercial | 10 | Original policy ↗ |
| Clotting Factors, Coagulant Blood Products, & Other Hemostatics | 2026D0047AN · Effective Oct 1, 2026 · Commercial | 39 | Original policy ↗ |
| Co-Surgeon / Team Surgeon Policy, Professional | Commercial | 5 | Original policy ↗ |
| Cochlear Implants | 2026T0070II · Effective Jun 1, 2026 · Commercial | 10 | Original policy ↗ |
| Cognitive Rehabilitation and Coma Stimulation | 2026T0144II · Effective Jul 1, 2026 · Commercial | 3 | Original policy ↗ |
| Collagen Crosslinks and Biochemical Markers of Bone Turnover | 2026T0419Z · Effective Jan 1, 2026 · Commercial | 1 | Original policy ↗ |
| Complement C5 Inhibitors | 2026D0049AE · Effective Apr 1, 2026 · Commercial | 5 | Original policy ↗ |
| Computer-Assisted Surgical Navigation for Musculoskeletal Procedures – Commercial and Individual Exchange Medical Policy | 2026T0599L · Commercial | 7 | Original policy ↗ |
